Try our Advanced Search for more refined results
Life Sciences
-
January 06, 2026
Top Personal Injury, Medical Malpractice Cases Of 2025
A headline-grabbing $329 million wrongful death verdict against Tesla and a landmark $2.5 billion deal between DuPont and New Jersey over PFAS "forever chemicals" are among Law360's top personal injury and medical malpractice cases from 2025.
-
January 05, 2026
1st Circ. Upholds Block On Trump Admin NIH Funding Cuts
The First Circuit on Monday affirmed a Massachusetts federal judge's order permanently blocking the Trump administration from gutting National Institutes of Health funding for biomedical research, agreeing that the government didn't have the authority to cap indirect costs for research grants.
-
January 05, 2026
Fed. Circ. Examines Timing Of $452M Trade Secrets Suit
A Federal Circuit panel delved into the statute of limitations for trade secrets cases Monday, pressing an attorney for a South Korean company seeking to reverse a verdict that prompted a $452 million jury award to explain why the clock should start when a plaintiff suspects misappropriation rather than when it is actually discovered.
-
January 05, 2026
Express Scripts Wants FTC Atty Views On Insulin Prices
Express Scripts is seeking to force an attorney from the Federal Trade Commission to sit for a deposition in the agency's case accusing pharmacy benefit managers of inflating insulin prices, saying the commission's own attorneys acknowledge that manufacturers cause higher prices.
-
January 05, 2026
Cancer Biotech Co. Eyes $182M IPO
A company developing new drugs for treating cancer disclosed Monday it is looking to raise roughly $182 million in an initial public offering guided by Paul Hastings LLP and Davis Polk & Wardwell LLP, teeing it up for the first major IPO of 2026.
-
January 05, 2026
Aetna Drug Price-Fixing Suit Against Pharma Cos. Paused
A judge has paused Aetna Inc.'s Connecticut Superior Court lawsuit accusing nearly two dozen pharmaceutical companies of fixing the prices of generic drugs, refusing drugmakers' bids to dismiss the case but agreeing to put it on hold pending the outcomes of similar cases in other jurisdictions.
-
January 05, 2026
3rd Circ. Won't Rethink Tax On Interest In $191M Pharma Deal
The Third Circuit declined to reconsider its decision that a pharmaceutical company's $191 million payment settling a family feud was for the sale of a family trust's ownership shares and included interest that should be taxed as ordinary income.
-
January 05, 2026
Health Officials Roll Back Child Vaccine Recommendations
Amid public outcry, federal health officials on Monday revised vaccine recommendations for American children, cutting the number from 18 to 11 and bringing the United States in line with other developed countries such as Denmark.
-
January 05, 2026
Ind. Sues Eli Lilly Over 'Grossly Inflated' Insulin Prices
Indiana's attorney general on Monday announced a state court suit against Eli Lilly alleging it schemed to artificially inflate the price of insulin, saying the litigation follows two years of ultimately unsuccessful attempts to resolve the matter without litigation against the drug manufacturer.
-
January 05, 2026
Trump Backs Biden's Medicare Drug Price Law At High Court
The Trump administration is defending the Biden-era Medicare Drug Price Negotiation program to the U.S. Supreme Court, asking the justices to deny AstraZeneca's petition challenging the program as unconstitutional.
-
January 05, 2026
Thesis Supplements Illegally Sold As ADHD Drugs, Suit Says
A Louisiana woman is suing the owner of Thesis Nootropics in New York federal court, alleging that the company's line of supplements is illegally marketed as an alternative to Adderall and other medications despite lacking federal approval.
-
January 05, 2026
Paul Hastings Adds Hogan Lovells Duo To Life Sciences Team
Two longtime Hogan Lovells partners, including the head of its pharmaceutical and biotechnology regulatory practice, have joined Paul Hastings LLP in Washington, D.C., the firm announced Monday.
-
January 02, 2026
Catching Up With Delaware's Chancery Court
Delaware's Court of Chancery paddled through mostly calm waters at the year's end, with plenty of big hearings and decisions in its rearview mirror, including a recent Chancery reversal restoring Elon Musk's compensation package, earlier valued at $56 billion.
-
January 02, 2026
IRS Floats Updates To Fee Paid By Brand Drugmakers
The Internal Revenue Service floated updates to regulations governing how branded prescription drug manufacturers or importers should calculate an annual fee established by the Affordable Care Act, a move the agency said aims to incorporate changes in drug discount programs and clarify tax reporting.
-
January 02, 2026
Drug Pricing Battles To Watch In 2026
With drugmakers already pushing back on drug affordability programs and policies, Law360 looks at the year ahead for litigation focused on state and federal drug pricing programs.
-
January 02, 2026
Product Liability Cases To Watch In 2026
Trials in the massive litigation against social media giants like Facebook are set to start in the New Year, as litigants battle over whether the companies should be held responsible for allegedly designing their platforms to addict youth, causing a bevy of mental health harms, and cases against popular weight loss drugs like Ozempic continue to mount. Here's what else product liability attorneys will be watching in 2026.
-
January 02, 2026
Patent Litigation Trends To Watch In 2026
Attorneys are expecting a significant increase in district court litigation after a series of dramatic changes at the U.S. Patent and Trademark Office have made the Patent Trial and Appeal Board less attractive, which is one of the most significant trends for 2026.
-
January 02, 2026
Antitrust Cases Ahead: Live Nation, Middleman On Trial
The U.S. Department of Justice and Federal Trade Commission enter 2026 with decisions to make about how to regroup after coming up short in major cases against Google and Meta Platforms.
-
January 02, 2026
Trade Secret Trends To Watch In 2026
The landscape of trade secret law could see significant developments in 2026 as courts address the aftermath of astronomical jury awards and navigate jurisdictional tensions surrounding the timing and specifics of trade secret disclosures in litigation.
-
January 02, 2026
NC Legislation To Watch In 2026: Healthcare Funding In Focus
A spate of healthcare legislation is on the line as North Carolina lawmakers get ready to return to the General Assembly in January, from tenuous funding for Medicaid and Planned Parenthood to efforts to control the Tar Heel state's skyrocketing healthcare costs.
-
January 02, 2026
California Cases To Watch In 2026
Legal experts following California courts in 2026 are tracking high-stakes personal injury, antitrust and copyright battles against giants in the social media, artificial intelligence and entertainment industries, as well as wide-ranging legal disputes arising from Los Angeles wildfires and high-profile appeals pending before the California Supreme Court.
-
January 02, 2026
Patent Policy To Watch In 2026
After a year of significant shifts in U.S. Patent and Trademark Office policy on patent reviews and patent eligibility, attorneys will be closely following how the changes play out in 2026, along with proposals for further moves, and whether Congress decides to weigh in on patents.
-
January 02, 2026
North Carolina Cases To Watch In 2026
In the new year, North Carolina state and federal courts are set to consider the intricacies of class action certification at the behest of thousands of fast-food workers and whether Chinese company TikTok Inc. is deliberately designing the app to addict children.
-
January 02, 2026
New Jersey Cases To Watch In 2026
In the coming year, New Jersey litigators will be watching for the outcome of an appeal in a constitutional challenge to school segregation and an employment discrimination case brought by a former Johnson & Johnson attorney.
-
January 02, 2026
What To Watch In Massachusetts Courts In 2026
Massachusetts attorneys have their eye on Trump administration policy challenges, state ballot question disputes and False Claims Act enforcement shifts as the calendar turns to 2026.
Expert Analysis
-
Texas Suit Marks Renewed Focus On Service Kickback Theory
After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.
-
Series
Power To The Paralegals: How And Why Training Must Evolve
Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy.
-
Series
Playing Softball Makes Me A Better Lawyer
My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty.
-
5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting
As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.
-
Fed. Circ. In August: A Framework For AIA Derivation Disputes
In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.
-
USPTO's Track One A Reliable Patent Pathway Amid Backlog
As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.
-
Vanda Ruling Opens Door For Contesting FDA Drug Denials
The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.
-
Series
Law School's Missed Lessons: Mastering Time Management
Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.
-
Rare Del. Oversight Ruling Sends Governance Wake-Up Call
An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.
-
How Hyperlinks Are Changing E-Discovery Responsibilities
A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.
-
Pharma Copay Programs Raise Complex Economic Questions
The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.
-
State False Claims Acts Can Help Curb Opioid Fund Fraud
State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.
-
Beaming Up Lessons From William Shatner's Failed Patent Bid
In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.
-
The Pros And Cons Of Levying Value-Based Fees On Patents
The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.
-
Series
Writing Musicals Makes Me A Better Lawyer
My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.